Abstract:A current in silico study investigates baxdrostat and 22 related compounds for their affinity to aldosterone synthase through molecular docking. Molecular dynamics simulation assesses the stability of these compound‐protein complexes. Drug‐likeness and ADMET properties are under scrutiny, complemented by a review of existing in vitro and in vivo studies. Resistant hypertension, a severe condition affecting about 10 % of people with high blood pressure, significantly increases the risk of heart, brain, and kidney issues. This study investigates the potential of baxdrostat and its derivatives (1–22) as aldosterone synthase inhibitors for resistant hypertension using in silico methods. The study employed various computational methods, including molecular dynamics simulation (MD), molecular docking, frontier molecular orbital (FMO) analysis, and global chemical descriptors, to evaluate the interactions between the compounds and the target proteins. The docking results showed that compounds 2, 5, 7, and baxdrostat had binding affinities of −7.8 kcal/mol, −10.9 kcal/mol, −10.6 kcal/mol, and −9.3 kcal/mol, respectively. Additionally, molecular dynamics simulations revealed that ligands 2, 5, and baxdrostat formed the most stable protein‐ligand complexes with aldosterone synthase. The complex of the 4FDH‐baxdrostat remained highly stable across all tested temperatures (300 K, 305 K, 310 K, and 320 K), consistently displaying low RMSD values, with the minimum observed at 305 K. Baxdrostat emerges as the most promising candidate among the compounds examined, showcasing notable potential when considering a combination of in vitro, in vivo, and now in silico data. While baxdrostat remains the primary candidate based on comprehensive in vitro, in vivo, and in silico studies, further analysis using FMO theory suggests that ligands 2 and 5 have promising potential due to their smaller Egap. To validate these findings, further clinical investigations are warranted.

Discovery of Benzimidazole Derivatives as Novel Aldosterone Synthase Inhibitors: QSAR, Docking Studies, and Molecular Dynamics Simulation?

Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase

Investigating Baxdrostat and Its Derivatives as Aldosterone Synthase Inhibitors for Resistant Hypertension: An In Silico Approach

Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment

A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase

Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2

3D-QSAR Studies of 2,4-Thiazolidinediones As Aldose Reductase Inhibitors Using CoMFA,CoMSIA and Molecular Docking

Design, Synthesis and Biological Evaluation of 6-Substituted Aminocarbonyl Benzimidazole Derivatives As Nonpeptidic Angiotensin II AT1 Receptor Antagonists.

A Selectivity Study of Benzenesulfonamide Derivatives on Human Carbonic Anhydrase II/IX by 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: Old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension

Exploring the Structural Determinants of Novel Xanthine Derivatives As A2B Adenosine Receptor Antagonists: a Computational Study

Combined Pharmacophore Modeling, 3D-Qsar, Homology Modeling and Docking Studies on Cyp11b1 Inhibitors

Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities

Discovery of Novel, Potent and Low-Toxicity Angiotensin Ii Receptor Type 1 (at(1)) Blockers: Design, Synthesis and Biological Evaluation of 6-Substituted Aminocarbonyl Benzimidazoles with A Chiral Center

Synthesis and Biological Activity of 2-Alkylbenzimidazoles Bearing a N-phenylpyrrole Moiety As Novel Angiotensin II AT1 Receptor Antagonists

Synthesis, molecular docking, enzyme inhibition and antioxidant potential of new 1H-benzo[ d ]imidazole-5-carboxamide derivatives

Synthesis of 5-amido-1H-imidazo[5,4-b]pyridine derivatives and their angiotensin II receptor antagonistic activities

Design, Synthesis, and Biological Evaluation of 1,2,4-Triazole Bearing 5-Substituted Biphenyl-2-sulfonamide Derivatives As Potential Antihypertensive Candidates

Design, Synthesis And 3d-Qsar Study Of 2-[N '-(2-Aryloxyethyl)Piperazinomethyl]-Benzoxazole Series As Alpha(1)-Adrenoceptor Antagonists

Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.